Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E-Submission Part Of FDA Reg Reform Plan; Alzheimer’s Data Standard About To Debut

Executive Summary

Standards for organizing clinical data from research in some major diseases are taking shape as FDA moves to clear a regulatory path that eventually could allow all submissions to be done electronically.

You may also be interested in...



Sponsors Might Share Research Committees As Pressure Mounts To Share Data

Novartis official says the firm is considering using the same committee as other sponsors to review requests from researchers for data access; stakeholders ask for seats at the table and data interoperability.

Chelsea Vows To Resolve Latest Regulatory Woes With Northera Quickly

Technical deficiencies foil the resubmission of Chelsea Therapeutics’ Northera. The company thinks it can resolve the problems quickly and some analysts expect a relatively short delay of one or two months to the user fee date.

Track-and-Trace Bill Clears House With New Electronic Labeling Language

Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.

Related Content

Topics

UsernamePublicRestriction

Register

PS053714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel